74 results
Page 2 of 4
8-K
EX-10.4
fc62s3ee z9
15 Jun 21
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
4:03pm
8-K
EX-10.1
6r4xy 7r0e
15 Jun 21
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
4:03pm
8-K
EX-10.2
d32vvzpa1f37jwcvmct
15 Jun 21
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
4:03pm
8-K
EX-10.5
x6qmewaopdoh9
15 Jun 21
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
4:03pm
8-K
EX-10.1
r6kplwm9 ae2bjhxwge2
3 Jun 21
Departure of Directors or Certain Officers
4:01pm
8-K
EX-10.1
ucsln qql1
29 Mar 21
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.1
qoe20hh9hjxu
10 Feb 20
INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS
9:22am
8-K
EX-10.1
ttckla5s0usd3v
27 Jan 20
Entry into a Material Definitive Agreement
5:24pm
8-K/A
EX-10.3
kdo0 xcsix1
24 May 19
Entry into a Material Definitive Agreement
4:12pm
8-K
EX-10.1
vuyzt7j8j7 n3k6v2
17 May 19
Entry into a Material Definitive Agreement
2:43pm
8-K
EX-10.2
eg8hkh
17 May 19
Entry into a Material Definitive Agreement
2:43pm
8-K
EX-10.1
p0h zlki9m0w
16 May 19
INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update
6:06am
8-K
EX-10.2
7ilyfcpf
16 May 19
INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update
6:06am
S-1/A
EX-10.21
2axoadbd04v4r
26 Sep 18
IPO registration (amended)
12:00am